– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
– Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20shot%20of%20a%20Broadcom%20chip%20by%20g0d4ather%20via%20Adobe%20Stock.jpeg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)
/Apple%20logo%20-%20by%20Pexels%20via%20Pixabay.jpg)